Novo Nordisk (NONO.F) Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
NONO.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 39.71 |
| 52 Week High | DKK 82.50 |
| 52 Week Low | DKK 34.00 |
| Beta | 0.27 |
| 1 Month Change | 11.51% |
| 3 Month Change | -34.58% |
| 1 Year Change | -33.82% |
| 3 Year Change | -53.23% |
| 5 Year Change | 7.44% |
| Change since IPO | 136.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| NONO.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.3% | -1.1% | 3.6% |
| 1Y | -33.8% | 30.7% | 39.4% |
Return vs Industry: NONO.F underperformed the US Pharmaceuticals industry which returned 31.9% over the past year.
Return vs Market: NONO.F underperformed the US Market which returned 38.7% over the past year.
Price Volatility
| NONO.F volatility | |
|---|---|
| NONO.F Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: NONO.F has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NONO.F's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 69,150 | Maziar Doustdar | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NONO.F fundamental statistics | |
|---|---|
| Market cap | US$180.45b |
| Earnings (TTM) | US$16.15b |
| Revenue (TTM) | US$48.74b |
Is NONO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NONO.F income statement (TTM) | |
|---|---|
| Revenue | DKK 309.06b |
| Cost of Revenue | DKK 54.38b |
| Gross Profit | DKK 254.69b |
| Other Expenses | DKK 152.25b |
| Earnings | DKK 102.43b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 06, 2026
| Earnings per share (EPS) | 23.09 |
| Gross Margin | 82.41% |
| Net Profit Margin | 33.14% |
| Debt/Equity Ratio | 63.1% |
How did NONO.F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/20 04:23 |
| End of Day Share Price | 2026/04/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novo Nordisk A/S is covered by 56 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Gerhard Schwarz | Baader Helvea Equity Research |
| José Romero Herrero | Banco Santander |